本文選題：甲狀腺乳頭狀癌 + 甲狀腺自身抗體��； 參考：《中國微創(chuàng)外科雜志》2017年02期

【摘要】：目的探討甲狀腺結(jié)節(jié)患者甲狀腺自身抗體與甲狀腺乳頭狀癌(papillary thyroid carcinoma,PTC)發(fā)生風險之間的相關(guān)性。方法回顧性分析2012年1月~2014年12月我院2128例因甲狀腺結(jié)節(jié)行手術(shù)治療的臨床和病理資料,其中PTC 807例(37.9%),良性結(jié)節(jié)1321例(62.1%)。采用logistic回歸分析,評價年齡、性別、病理診斷的慢性淋巴細胞性甲狀腺炎(chronic lymphocytic thyroiditis,CLT)、甲狀腺球蛋白抗體(thyroglobulin antibody,TGAb)、甲狀腺過氧化物酶抗體(thyroid peroxidase antibody,TPOAb)、促甲狀腺激素(thyroid stimulating hormone,TSH)等因素與PTC發(fā)生風險的相關(guān)性。結(jié)果與良性結(jié)節(jié)組相比,PTC組年齡更小[中位數(shù)43(四分位數(shù)33,53)歲vs.51(39,59)歲,P=0.000],合并CLT的比率更高[27.1%(219/807)vs.12.7(168/1321),P=0.000],TGAb陽性比率更高[26.6%(215/807)vs.13.7%(181/1321),P=0.000],TPOAb陽性比率更高[26.0%(210/807)vs.18.8%(249/1321),P=0.000],血清TSH水平更高[1.67(1.11,2.37)m IU/L vs.1.42(0.91,2.12)m IU/L,P=0.000]。多因素logistic回歸分析顯示,合并CLT(OR=1.843,95%CI:1.375~2.471,P=0.000)及TGAb陽性(60~99 U/ml組OR=2.005,95%CI:1.237~3.249,P=0.005;≥500 U/ml組OR=2.146,95%CI:1.281~3.594,P=0.004)與PTC發(fā)生風險獨立相關(guān),而TPOAb陽性與PTC發(fā)生風險未見獨立相關(guān);此外,PTC的發(fā)生風險隨TSH水平的升高而增加。結(jié)論甲狀腺結(jié)節(jié)合并CLT、TGAb陽性及TSH水平升高與PTC發(fā)生風險增加相關(guān)。
[Abstract]:Objective to investigate the relationship between thyroid autoantibodies and the risk of papillary thyroid carcinoma in thyroid nodules. Methods from January 2012 to December 2014, the clinical and pathological data of 2128 cases of thyroid nodule treated by operation in our hospital were retrospectively analyzed. Among them, there were 807 cases with PTC and 37.9 cases with benign nodule and 1321 cases with benign nodule. Logistic regression analysis was used to evaluate age and sex. The relationship between chronic lymphocytic thyroiditis, thyroid globulin antibody, thyroid peroxidase antibody, thyrotropin stimulating hormonet, and so on were correlated with the risk of PTC in the pathologically diagnosed chronic lymphocytic thyroiditis. 緇撴灉涓庤壇鎬х粨鑺傜粍鐩告瘮,PTC緇勫勾榫勬洿灝廩涓綅鏁，

本文編號：1926033